Serina Therapeutics, Inc. (SER)
NYSEAMERICAN: SER · Real-Time Price · USD
1.850
+0.050 (2.78%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Serina Therapeutics Employees
As of December 31, 2024, Serina Therapeutics had 13 total employees, including 12 full-time and 1 part-time employees. The number of employees increased by 2 or 18.18% compared to the previous year.
Employees
13
Change (1Y)
2
Growth (1Y)
18.18%
Revenue / Employee
$10,000
Profits / Employee
-$1,495,077
Market Cap
22.78M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 13 | 2 | 18.18% |
| Dec 31, 2023 | 11 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Vistagen Therapeutics | 59 |
| Curis | 24 |
| Jasper Therapeutics | 22 |
| OSR Holdings | 22 |
| ABVC BioPharma | 19 |
| NeuroSense Therapeutics | 17 |
| Barinthus Biotherapeutics | 14 |
| Lexaria Bioscience | 7 |
SER News
- 21 days ago - Serina Therapeutics to Present at the 5th LNP Formulation & Process Development Summit - GlobeNewsWire
- 26 days ago - Serina Therapeutics Announces NYSE American Acceptance of Continued Listing Compliance Plan - GlobeNewsWire
- 5 weeks ago - Serina Therapeutics to Present at the 38th Annual Roth Conference - GlobeNewsWire
- 5 weeks ago - Serina Therapeutics Secures up to $30 Million in Private Placement to Advance Registrational Trial of SER-252 for Advanced Parkinson's Disease - GlobeNewsWire
- 2 months ago - Serina Therapeutics Announces Dosing of First Patient in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson's Disease - GlobeNewsWire
- 2 months ago - Serina Therapeutics Announces First Patient Enrolled in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson's Disease - GlobeNewsWire
- 3 months ago - Registration Is Now Open For Tribe Public's CEO Presentation and Q&A Webinar Event - GlobeNewsWire
- 3 months ago - Serina Therapeutics Announces FDA Clearance of IND Application for SER-252 for the Treatment of Advanced Parkinson's disease - GlobeNewsWire